CONTEXT: RWD, in this case US claims database, used to analyse disease progression measures for patients on edaravone (Radical). Results were presented at the AAN virtual meeting. This report does Continue Reading
CONTEXT: This is a serious amount of data that OM1 have managed to amass on Rheumatoid Arthritis patients, with over 200,000 adults and over 5000 juveniles being followed in registries. Continue Reading
CONTEXT: Another commercial announcement of a tie up on RWD sources | US only. IMPACT: Low READ TIME: 1 min Quality Level Mean [1 – 10]: 3 1. “Through the Continue Reading
CONTEXT: Commercial announcement of another pharmaceutical company securing access to RWD, in this case across oncology centres in France. IMPACT: Medium READ TIME: 1 min Quality Level Mean [1 – Continue Reading
CONTEXT: Whilst this story is not directly related to health data, we think it is worth a read. It feels like we are hearing about new terminology every day, but Continue Reading
CONTEXT: Commercial announcement of RWD use in angioedema IMPACT: low READ TIME: 1 min Quality Level Mean [1 – 10]: 5 1. “ICER’s updated assessment will leverage observational RWE analyzed Continue Reading
CONTEXT: Commercial announcement of yet another RWD tie-up. IMPACT: Low READ TIME: 1 min Quality Level Mean [1 – 10]: 2 1. “FAIRFAX, Va., April 7, 2021 /PRNewswire/ Continue Reading
CONTEXT: Yet another announcement of a venture capital funded company focused on commercialising real-world data sources | Are we opening up sources or slamming the door shut unless you have Continue Reading
CONTEXT: Commercial announcement of another in what is becoming the biggest rend this year – access to RWD. I don’t know about you, but I’m intrigued by the phrase “research Continue Reading
CONTEXT: At first glance this interview article about an app developed to measure a set of performance indicators may seem to be on the fringes of “proper science”. However, patients Continue Reading
